Purpose To describe the adverse events associated with local anaesthesia (LA) for intraocular surgery.
reported in association with all LA techniques.
In 3 months, 18 events were described as 'life threatening' by respondents, and further patients were reported to have had epileptic fits or were transferred directly from the operating theatre to an intensive care unit. The voluntary nature of the survey introduces some bias from under-reporting, making the incidence of these severe events difficult to assess. Reported incidence of severe 'systemic' adverse events was similar for all LA techniques.
Conclusions Serious adverse events were reported in association with all LA techniques.
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The methodology for the Survey has already been described in detail. aData on expulsive haemorrhage were specifically requested for patients who had LA in the first week, resulting in two of the four reports. As LA is not generally agreed to be a risk factor for expulsive haemorrhage, we did not expect many reports thereafter. b Occurred with combined retrobulbar + peribulbar anaesthesia (RBA + PBA). Total number of RBA + PBA in the 3 months was calculated to be 830 (95% CI: 550-1250).
Orbital Adverse Events are summarised in Tables 1a and lb. As would be expected from the Survey design, most reports of 'Minor' Adverse Events were from the first week. The tables therefore show the reported incidence of minor Adverse Events for the first week only (Table 1a ), but severe Adverse Events for the whole 3-month period (Tables la, 1b ).
The major Orbital Adverse Events associated with LA are globe perforation and retrobulbar haemorrhage.
Expulsive haemorrhage (acute intraoperative suprachoroidal haemorrhage), while frequently associated with a poor outcome, is not generally agreed to be a complication of LA itself. 4 7 ,48 For the first week of the Survey, the Report Form contained a specific request for each of these three Orbital events to be reported.
Thereafter, reporting of adverse events relied on the respondent recognising an adverse event to be related to the LA itself. We therefore did not expect many reports of expulsive haemorrhage after the first week.
The reported incidence of globe perforation with retrobulbar anaesthesia was 1:11 000, or 0. Less severe Systemic Adverse Events
No. of reports Description 17 3 hypertension (1 with ventricular ectopics; had pre-med.) 3 bradycardias (1 with pulsus bigemini, 1 with panic, 1 sedated pre-op.) 2 tachycardias (2 supraventricular, 1 sedated pre-op.) 1 palpitations 1 vasovagal faint 1 unspecified cardiovascular system problem (had pre-med.) 1 'totally uncooperative' 2 panic only (both sedated pre-op.) 2 deoxygenation (1 with claustrophobia, 1 sedated pre-op. Table 2c:  lines 5 and 7   see Table 2c: line 17 We looked at the characteristics of the 22 patients who had Severe Systemic Adverse Events, to see whether there were any features common to this group (Table 3) . Table 3 ). Mann-Whitney, chi-squared and 
Discussion
The Survey results confirm the widely held view that serious adverse events associated with LA are rare.
However, we have shown that adverse events are seen with all LA techniques, thus demonstrating that no LA is totally safe.
It is likely that the actual incidence of adverse events was higher than estimated in this paper. In calculating the number of LAs actually given during the Survey, we made a correction for the 72.8% participation rate in the initial week. In calculating the incidence of Adverse Events, we assumed that all such events had been reported (i.e. 100% participation for adverse events). Table 2a shows that 23 non-severe Systemic Adverse
Events were reported in the first week: if incidence and reporting had continued at the same rate, we would have expected a further 362 reports for the remainder of the Survey: the actual figure was 47, about one-eighth of that predicted. We suspect that there was also significant under-reporting of the more serious adverse events.
Causes of low-response bias could include: lack of awareness of the Survey, failure to recognise that the event had taken place or was eligible, not considering an adverse event to be severe enough for inclusion, forgetting that the Survey was still running, unwillingness to spend time completing an Adverse Event Form, concern that the report may engender further time-consuming correspondence, embarrassment if safety Guidelines had not been followed, overwork, apathy, suspicion of an underlying motive for the Survey, and fear of being 'policed' by the Royal Colleges.
We tried to minimise non-response bias from these causes by offering complete anonymity to respondents, From the incidents reported, we calculate that the number of life-threatening adverse events occurring annually in the United Kingdom is at least 100.
Depending on the degree of under-reporting, the true figure may be in the order of a few hundred.
The novel design of the Survey makes it difficult to compare incidence of adverse events with other studies.
Large case-series are often produced in centres with a special interest in LA safety, and as such their results may be better than average. As discussed above, we expect that the Survey suffered from a degree of under reporting of serious adverse events. There is also the problem that severity of adverse events is not well defined in all studies. In this Survey, the 22 cases that fulfilled our strict criteria as Severe Systemic Adverse An observational study of this type cannot answer the question of which LA technique is safest: this would require a prospective randomised trial so large that it could probably never be performed. However, it is interesting to compare the incidence of Severe Adverse
Events with the different LA techniques used in the Survey (Table 2b we felt that this would not be appropriate, the main ones being that a longer period of data collection could adversely affect participation, and that there is a wide range of LA injection techniques, some of which may be described as 'retrobulbar' by one clinician and 'peribulbar' by another. As discussed above, the observational design of the Survey does not permit direct comparisons to be made.
In Table 3 , we attempted to find any common features Adverse Events group may reflect a higher incidence of Minor Orbital events with lignocaine, a higher incidence of Systemic events with the other LA agents, or a random effect. Because this was not a prospective randomised study, Table 3 should not be considered as a direct comparison of safety. Thus, it cannot be used to argue for the safety or otherwise of any particular LA agent or of sedation.
There were no reports of death in the operating theatre for the 3-month Survey, though one patient suffered hypertension and tachycardia prior to his LA injection, and his death due to a myocardial infarction the following day was attributed to the stress of having Haider, personal communication). In view of the severity of some of the adverse events reported during our Survey, it is possible that timely intervention by anaesthetists prevented a number of deaths during the 3-month period.
Serious Systemic Adverse Events were reported in association with all LA techniques. Many of the events summarised in Table 3 However these events were caused, the fact that they were seen with all LA techniques implies that we should be prepared for serious adverse events in all patients who have intraocular surgery.
